|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kelloff GJ and Sigman CC: Cancer
biomarkers: selecting the right drug for the right patient. Nat Rev
Drug Discov. 11:201–214. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ono S: Mechanism of depolymerization and
severing of actin filaments and its significance in cytoskeletal
dynamics. Int Rev Cytol. 258:1–82. 2007.PubMed/NCBI
|
|
4
|
Hotulainen P, Paunola E, Vartiainen MK and
Lappalainen P: Actin-depolymerizing factor and cofilin-1 play
overlapping roles in promoting rapid F-actin depolymerization in
mammalian nonmuscle cells. Mol Biol Cell. 16:649–664. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhu B, Fukada K, Zhu H and Kyprianou N:
Prohibitin and cofilin are intracellular effectors of transforming
growth factor beta signaling in human prostate cancer cells. Cancer
Res. 66:8640–8647. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang W, Mouneimne G, Sidani M, et al: The
activity status of cofilin is directly related to invasion,
intravasation and metastasis of mammary tumors. J Cell Biol.
173:395–404. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Epstein JI: An update of the Gleason
grading system. J Urol. 183:433–440. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Prensner JR, Rubin MA, Wei JT and
Chinnaiyan AM: Beyond PSA: the next generation of prostate cancer
biomarkers. Sci Transl Med. 4:127rv32012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lilja H, Ulmert D and Vickers AJ:
Prostate-specific antigen and prostate cancer: prediction,
detection and monitoring. Nat Rev Cancer. 8:268–278. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wolf AM, Wender RC, Etzioni RB, et al:
American Cancer Society Prostate Cancer Advisory Committee:
American Cancer Society guideline for the early detection of
prostate cancer: update 2010. CA Cancer J Clin. 60:70–98. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Balk SP, Ko YJ and Bubley GJ: Biology of
prostate-specific antigen. J Clin Oncol. 21:383–391. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Castro MA, Dal-Pizzol F, Zdanov S, et al:
CFL1 expression levels as a prognostic and drug resistance marker
in nonsmall cell lung cancer. Cancer. 116:3645–3655. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang LH, Xiang J, Yan M, et al: The
mitotic kinase Aurora-A induces mammary cell migration and breast
cancer metastasis by activating the Cofilin-F-actin pathway. Cancer
Res. 70:9118–9128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Polachini GM, Sobral LM, Mercante AM, et
al: Proteomic approaches identify members of cofilin pathway
involved in oral tumorigenesis. PLoS One. 7:e505172012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang ZL, Miao X, Xiong L, et al: CFL1 and
Arp3 are biomarkers for metastasis and poor prognosis of squamous
cell/adenosquamous carcinomas and adenocarcinomas of gallbladder.
Cancer Invest. 31:132–139. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou J, Wang Y, Fei J and Zhang W:
Expression of cofilin 1 is positively correlated with the
differentiation of human epithelial ovarian cancer. Oncol Lett.
4:1187–1190. 2012.PubMed/NCBI
|
|
17
|
Nishimura S, Tsuda H, Kataoka F, et al:
Overexpression of cofilin 1 can predict progression-free survival
in patients with epithelial ovarian cancer receiving standard
therapy. Hum Pathol. 42:516–521. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li M, Yin J, Mao N and Pan L: Upregulation
of phosphorylated cofilin 1 correlates with taxol resistance in
human ovarian cancer in vitro and in vivo. Oncol Rep. 29:58–66.
2013.PubMed/NCBI
|
|
19
|
Chung H, Kim B, Jung SH, et al: Does
phosphorylation of cofilin affect the progression of human bladder
cancer? BMC Cancer. 13:452013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ren S, Ouyang DY, Saltis M, et al:
Anti-proliferative effect of 23,24-dihydrocucurbitacin F on human
prostate cancer cells through induction of actin aggregation and
cofilin-actin rod formation. Cancer Chemother Pharmacol.
70:415–424. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pérez-Martínez FC, Carrión B, Lucío MI, et
al: Enhanced docetaxel-mediated cytotoxicity in human prostate
cancer cells through knockdown of cofilin-1 by carbon nanohorn
delivered siRNA. Biomaterials. 33:8152–8159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
van Rheenen J, Song X, van Roosmalen W, et
al: EGF-induced PIP2 hydrolysis releases and activates cofilin
locally in carcinoma cells. J Cell Biol. 179:1247–1259. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Oser M and Condeelis J: The cofilin
activity cycle in lamellipodia and invadopodia. J Cell Biochem.
108:1252–1262. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yap CT, Simpson TI, Pratt T, Price DJ and
Maciver SK: The motility of glioblastoma tumour cells is modulated
by intracellular cofilin expression in a concentration-dependent
manner. Cell Motil Cytoskeleton. 60:153–165. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Partin AW, Carter HB, Chan DW, et al:
Prostate specific antigen in the staging of localized prostate
cancer: influence of tumor differentiation, tumor volume and benign
hyperplasia. J Urol. 143:747–752. 1990.PubMed/NCBI
|
|
26
|
Paquette EL, Connelly RR, Sun L, Paquette
LR and Moul JW: Predictors of extracapsular extension and positive
margins in African American and white men. Urol Oncol. 21:33–38.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Asbell SO and Vijayakumar S: Racial
differences in prostate-specific antigen levels in patients with
local-regional prostate cancer. Prostate. 31:42–46. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Moul JW, Connelly RR, Mooneyhan RM, et al:
Racial differences in tumor volume and prostate specific antigen
among radical prostatectomy patients. J Urol. 162:394–397. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Resnick MJ, Canter DJ, Guzzo TJ, et al:
Does race affect postoperative outcomes in patients with low-risk
prostate cancer who undergo radical prostatectomy? Urology.
73:620–623. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Magheli A, Rais-Bahrami S, Trock BJ, et
al: Prostate specific antigen versus prostate specific antigen
density as a prognosticator of pathological characteristics and
biochemical recurrence following radical prostatectomy. J Urol.
179:1780–1784. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Giannarini G, Scott CA, Moro U, Pertoldi
B, Beltrami CA and Selli C: Are PSA density and PSA density of the
transition zone more accurate than PSA in predicting the
pathological stage of clinically localized prostate cancer? Urol
Oncol. 26:353–360. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nishimoto K, Nakashima J, Hashiguchi A, et
al: Prediction of extraprostatic extension by prostate specific
antigen velocity, endorectal MRI, and biopsy Gleason score in
clinically localized prostate cancer. Int J Urol. 15:520–523. 2008.
View Article : Google Scholar : PubMed/NCBI
|
